{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-001712","form_type":"8-K/A","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2025-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.926216+00:00","generated_at":"2026-05-24T11:42:02.666949+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xenetic Biosciences reports FY2024 net loss of ~$4.0M, cash $6.2M, advances DNase program","bullets":["Net loss for FY2024 ~$4.0M; R&D expenses $3.3M (down 5.9% YoY), G&A $3.4M (down 4.1%).","Royalty payments from Takeda sublicense ~$2.5M, flat YoY; cash balance $6.2M at year-end.","Entered Clinical Trial Services Agreement with PeriNess for DNase I studies in pancreatic, colorectal, and solid tumors.","Extended collaborations with University of Virginia and Scripps Research through 2025.","Progressing DNase I development program toward IND and first-in-human study for pancreatic carcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-001712","json":"https://secwatch.observer/filing/0001683168-25-001712.json","markdown":"https://secwatch.observer/filing/0001683168-25-001712.md","text":"https://secwatch.observer/filing/0001683168-25-001712.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316825001712/0001683168-25-001712-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316825001712/xenetic_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T11:42:02.666949+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}